Survey of intravitreal injection outcomes amongst ophthalmologists using pre-filled aflibercept syringes

Clin Exp Ophthalmol. 2022 Sep;50(7):803-805. doi: 10.1111/ceo.14125. Epub 2022 Jun 30.

Authors

Daniel J Lee¹, Brittni A Scruggs¹, Ambar Faridi^{1

2}, Erik Sánchez³, Merina Thomas¹

Affiliations

¹ Casey Eye Institute, Department of Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA.
² Department of Ophthalmology, Veteran Affairs Portland Health Care System, Portland, Oregon, USA.
³ Department of Physics, Portland State University, Portland, Oregon, USA.

No abstract available

Publication types

Letter

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Humans
Intravitreal Injections
Ophthalmologists*
Ranibizumab
Receptors, Vascular Endothelial Growth Factor
Recombinant Fusion Proteins / therapeutic use
Syringes

Substances

Angiogenesis Inhibitors
Recombinant Fusion Proteins
aflibercept
Receptors, Vascular Endothelial Growth Factor
Ranibizumab

Grants and funding

P30 EY010572/EY/NEI NIH HHS/United States